Anti-Coagulants - Namibia | Statista Market Forecast

Namibia is projected to see a revenue of US$2.72m in the Anti-Coagulants market by 2024.
This market is expected to experience an annual growth rate (CAGR 2024-2029) of 6.98%, leading to a market volume of US$3.81m by 2029.
In comparison to other countries, United States is anticipated to generate the highest revenue of US$16.74bn in 2024.
Namibia has seen a steady increase in the demand for anti-coagulants due to the growing elderly population and rising cases of cardiovascular diseases.

Definition:
The Anti-Coagulants market covers drugs that prevent blood from clotting, i.e., that prolong the clotting time. Anti-coagulants are certain types of antithrombotics, which are often also called blood thinners. Neither thrombolytic drugs, which dissolve clots after they have formed, nor other anti-thrombotics, such as antiplatetelet drugs, are covered in this market.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol Myers Squibb, Bayer, Sanofi, Johnson & Johnson

Blood clotting inhibitors

Anti-fibrinolytics
Anti-hypertensives
Other hematology drugs
Other anti-thrombotic agents, such as platelet aggregation inhibitors
Thrombolytic drugs

The Anti-Coagulants market in Namibia is developing at a steady pace, driven by several factors that are shaping the healthcare industry in the country.

Customer preferences: Namibian customers are increasingly becoming aware of the benefits of anti-coagulants in preventing and treating blood clots. This has led to a growing demand for these drugs, particularly among the elderly population who are more susceptible to blood clotting disorders.

Trends in the market: The Anti-Coagulants market in Namibia is characterized by the growing popularity of direct oral anticoagulants (DOACs) over traditional anticoagulants such as warfarin. DOACs are preferred by patients due to their ease of use and lower risk of complications. This trend is expected to continue in the coming years, with DOACs projected to dominate the market.

Local special circumstances: Namibia has a small population of just over 2 million people, which limits the size of the Anti-Coagulants market. However, the country has a high burden of non-communicable diseases such as cardiovascular disease, which increases the demand for anti-coagulants. The country also has a shortage of healthcare professionals, which can make it difficult for patients to access these drugs.

Underlying macroeconomic factors: Namibia's economy has been facing challenges in recent years, with slow growth and high unemployment rates. This has led to a decrease in government spending on healthcare, which can limit the availability of anti-coagulants in public hospitals and clinics. However, the private healthcare sector is growing, driven by increasing demand for quality healthcare services. This presents an opportunity for pharmaceutical companies to tap into the private market and expand their reach in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.